Parameter* Patients
(N = 27,564)
Baseline LDL-C, mg/dL (median interquartile range) 92 (80 - 109)
Type of
atherosclerosis
MI
Nonhemorrhagic stroke
PAD
81%
19%
13%
Patients on at least 5 months of statin therapy1,3,‡ 70%
Baseline statin use High intensity
Moderate intensity
69%
30%
CV risk factors Hypertension
Type 2 diabetes mellitus
Current cigarette use
80%
36%
28%
Ezetimibe use 5%
Other cardiovascular
medications
Anti-platelet agents
Beta-blocker
ACE inhibitor
ARB
93%
76%
56%
23%

*Baseline patient characteristics from the Repatha® Outcomes Study (FOURIER).2

Patients could have more than one type of atherosclerosis.1

This provides a 19-week maximum measurement period of stable statin therapy, defined as high to moderate intensity statin background therapy at randomization consisting of an effective statin dose of atorvastatin at least 20 mg, or equivalent.1,3